Abingworth and Gilead Sciences have formed a strategic financing agreement to provide up to $210 million for the clinical development of Trodelvy® for non-small cell lung cancer, indicating a promising collaboration in the biopharmaceutical sector.

Target Information

Gilead Sciences, a prominent biopharmaceutical company, has entered into a strategic financing agreement with Abingworth, a distinguished international life sciences investment group. This agreement aims to accelerate the clinical development of Trodelvy® (sacituzumab govitecan-hziy) in the treatment of non-small cell lung cancer. As part of the agreement, Gilead retains complete rights to Trodelvy, ensuring that the innovation and drug deployment remain within its management.

The financing will provide up to $210 million to support key clinical studies. Furthermore, the collaboration includes the establishment of a Joint Steering Committee overseen by both Launch Therapeutics—a clinical development entity backed by Abingworth and Carlyle— and Gilead, emphasizing the commitment to drive the therapeutic development forward efficiently.

Industry Overview

The biopharmaceutical industry in the United Kingdom is one of the most advanced globally, consistently leading in innovative drug development and approval processes. Significant investments in research and development have fostered a conduc